Evidence map›Paper›PMID 26124174›Full record

ArticleAntimicrobial agents and chemotherapy2015

In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.

Min Kyeong Cha, Cheol-In Kang, So Hyun Kim, Sun Young Cho, Young Eun Ha, Yu Mi Wi, Doo Ryeon Chung, Kyong Ran Peck, Jae-Hoon Song, Korean Network for Study on Infectious Diseases (KONSID)

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Min Kyeong ChaAsia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea.
Cheol-In KangDivision of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea collacin@hotmail.com.
So Hyun KimAsia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Sun Young ChoDivision of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Young Eun HaDivision of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yu Mi WiDivision of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Doo Ryeon ChungAsia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kyong Ran PeckDivision of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jae-Hoon SongAsia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Korean Network for Study on Infectious Diseases (KONSID)
Sungkyunkwan University · KRSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the in vitro activity of various antimicrobials alone and in combination against 291 extended-spectrum-β-lactamase-producing Escherichia coli (ESBL-EC) isolates causing bacteremia in South Korean hospitals. Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin showed greater activity than found in combination with ciprofloxacin. In settings with a high prevalence of ESBL-producing pathogens, combination aminoglycoside antimicrobial therapy, especially with amikacin, may be considered for empirical therapy against suspected Gram-negative sepsis as a carbapenem-saving strategy.

Indexed as

AminoglycosidesAnti-Bacterial AgentsBacteremiabeta-LactamasesCefiximeCeftazidimeEscherichia coliFluoroquinolonesMicrobial Sensitivity TestsPenicillanic AcidPiperacillinTazobactamAminoglycosidesAnti-Bacterial Agentsbeta-LactamasesCefiximeCeftazidimeFluoroquinolonesPenicillanic AcidPiperacillinTazobactam

Identifiers

PMID26124174
PMCPMC4538563
OpenAlexW1801695937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.